15 Jun 09
Unless it paints the right picture youâre letting the side down!
In a depressed job market, an employer is likely to receive 50+ CVs per job advertised from 5 or more Preferred Agencies and many more from agencies who âpiggy backâ in. So now, more than ever, your CV needs to stand out and be tailored to the role and client and submitted by an agency with valid access.
Avril Horn PhD
12 Jun 09
Datamonitor attended the American Society of Clinical Oncology's 45th Annual Meeting in Orlando, Florida, to assess the key highlights of the conference. A number of promising presentations evaluated the potential of currently marketed agents to successfully combine with conventional chemotherapy in indications with persistent high unmet needs.
11 Jun 09
Dr Wolfgang Wein, Executive Vice-President of Merck Seronoâs Oncology Business comments on the recent final appraisal determination by NICE paving the way for its leading oncology product Erbitux to benefit UK mCRC patients.
Olwen Glynn Owen - Pharmiweb Field reporter
05 Jun 09
Despite the pharmaceutical industry's evolving business model in response to growing regulatory constraints, the sector is facing unprecedented challenges caused by the economic downturn and President Obama's planned overhaul of the US healthcare system. To continue on its journey towards 'Pharma 2.0', the industry must balance the more pressing short term issues against longer term trends
Priyanka Adhikari - Datamonitor
01 Jun 09
The Department of Health is determined to improve commissioning, and it will do whatever it takes to make it happen. That is the message that senior departmental officials sent to practice based commissioners last week at a National Association of Primary Care conference in London.
01 Jun 09
The time has arrived for primary care trusts to shed their provider functions, and it is causing considerable angst in the community services sector. It was inevitable that sooner or later, the split would have to happen, but now the race is on to decide what organisation model they want to adopt: foundation trust or social enterprise?
20 May 09
Senior Department of Health executives, speaking at a recent NHS Alliance Conference, suggested that the NHS has two years left before it starts to the credit crunchâs bite â maybe less if there is an election in a yearsâ time. But this should not be cause complacency in the health sector. The message is, invest wisely now so that you are well prepared for the fallow times ahead.
18 May 09
The growing incidence of diseases and conditions related to aging is creating pockets of opportunity for pain management. These opportunities include the expanding use of prescription NSAIDs as second-line therapies for chronic pain and an increase in off-label prescribing. As populations and indications evolve, so too is the pain management sector.
Applied Data Research
14 May 09
In this edition of StrategicEdge, CBR Pharma Insights discusses the current trends and opportunities that exist in marketing to consumers as the age of TiVo, DVRs, and cost constraints point the industry towards creative uses of the internet and other e-technologies.
CBR Pharma Insights
13 May 09
Integrated Care Organisations (ICOs) are the new kids on the block, and tipped as the natural successor to practice based commissioning.
11 May 09
The recent outbreak of influenza A (H1N1) infection, previously referred to as swine flu, has thrown the spotlight on governments around the world and their ability to manage a pandemic. In the UAE, customers are currently finding it difficult to source antivirals but, with Dubai seen as a hub for international travel, the government has stockpiles ready for distribution should an outbreak occur.
08 May 09
There has been no shortage of conversation lately about current problems facing the Pharmaceutical industry...
08 May 09
At least 1.3 billion people worldwide lack access to the most basic healthcare, with this burden being greatest in countries overwhelmed by poverty. Since the gap between rich and poor is widening, the Global Health Education Foundation (GHEF: www.globalhef.org) has been set up to tackle worsening disparities in healthcare.
Dr John Wei
06 May 09
The inspiration for this article came to me when watching an interview with Mr N R Narayanmurthy, Chief Mentor at Infosys. I was particularly taken by his control and poise; clearly, someone with years of training and experience in being interviewed can be completely at ease in such a stressful situation, but it made me think about how we can all improve our own techniques and create that vital positive first impression.
05 May 09
As part of the UK government's drive to save over GBP2 billion in the NHS during 2010-11, GBP550m will be cut from the prices of branded drugs as a result of the revised Pharmaceutical Price Regulation Scheme. With the volume of branded drugs having remained flat over the last four years, total sales of the UK branded pharmaceutical industry are forecast to decline from 2009 onwards.
30 Apr 09
The latest outbreak of influenza virus H1N1 âswine fluâ is now widely tipped to cause a global pandemic of unknown severity. Previously, the influenza vaccine community discussed the theoretical limitations of current technologies and capacity. Now they are faced with the reality of these limitations. VacZine Analytics believes H1N1 must change the science of influenza vaccines.
VacZine Analytics Group
28 Apr 09
How vehicle telematic systems could make sales representatives more efficient in terms of planning, reducing driving time, speed, fuel usgae, mileage and ahost of other benefits?
Reduce operating costs, increase productivity, improve customer service and monitor health and safety of your employees.
28 Apr 09
Public opinion has for long been regarded as essential to the success of a thriving business. In fact, whilst the benefits of popular perception can often appear somewhat intangible on the balance sheet, what is essentially the respect of the customer is the bastion of almost every profession
20 Apr 09
Despite the current economic downturn, pharmaceutical research & development spending continues to play a vital role in the pharmaceutical industry. The industry, as a whole, needs to find new, more innovative ways to compensate for the recent and upcoming patent loses of many blockbusters products...
CBR Pharma Insights
20 Apr 09
Any positive effect on the pharmaceutical industry derived from the G20 summit and European Union summit will be indirect and much of the direct healthcare spending increase will cover the cost of cheaper generics accessed through publically funded programs. Furthermore, emerging markets previously targeted to drive revenue growth face potentially crippling consequences from the downturn.
06 Apr 09
Medical communications provide professional, valuable marketing solutions to pharmaceutical companies, incorporating; writing, design, multimedia, conferences and events and more.
03 Apr 09
We have all heard the doom and gloom regarding the financial markets/ credit crunch/ recession. Itâs pretty hard to escape it. The high earning bankers are jobless and the face of our high street is changing with high profile collapses of organisations including Woolworths, the Officers Club, MFI and Barretts.
Chantal Williams- RSA executive search consultant
31 Mar 09
For some patients, namely those suffering from terminal illness, pain relief is an issue that talks to them about the right to end their lives in relative comfort and dignity. In such situations, new kinds of research that attack the complications and side effects of high level pain killers â such as opium based pain relievers â are particularly pertinent.
16 Mar 09
Adventis Health is one of a number of medical communications agencies that offers an integrated service with advertising, PR, Medical Education and digital media all available in house.
12 Mar 09
Latest research from strategic consultancy VacZine Analytics(R) suggests that the expert community is leaning towards the idea of priming the population now against a possible influenza pandemic. The concept referred to as pre emtive or âearlyâ immunological priming, is faced with obstacles, but possibly not as many as those linked with current pandemic vaccine strategies.
VacZine Analytics Group
11 Mar 09
In January, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful development and launch. While the main focus of the meeting the biosimilars market in the EU, it was widely agreed that developments in the US, and President Obama's handling of the generic biotech issue, will be the defining issue of 2009 and beyond.